Crispr Therapeutics AG: Strategic Progress and Strong Financials Bolstering a Buy Rating
Crispr Therapeutics AG Poised for Growth: Foroohar Maintains Buy Rating Amid Pipeline Progress and Strong Financials
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $105
Crispr Therapeutics AG (CRSP) Receives a Buy From Piper Sandler
Crispr Therapeutics Price Target Cut to $94.00/Share From $112.00 by Chardan Capital
CRISPR Therapeutics Analyst Ratings
Barclays Sticks to Its Hold Rating for Crispr Therapeutics AG (CRSP)
Chardan Research Adjusts Price Target on CRISPR Therapeutics to $94 From $112, Maintains Buy Rating
Buy Rating Affirmed for Crispr Therapeutics AG Amid Strong Commercial Prospects and Robust Pipeline Growth
Rodman & Renshaw Initiates CRISPR Therapeutics at Buy With $90 Price Target
TD Cowen Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $30
CRISPR Therapeutics Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Crispr Therapeutics AG (CRSP) and Tango Therapeutics (TNGX)
CRISPR Therapeutics Analyst Ratings
Citigroup Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $84
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)
Stifel Nicolaus Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics Analyst Ratings
Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating